Divergent gene expression through PI3K/akt signalling pathway cause different models of hypertrophy growth in chicken

被引:3
|
作者
Albooshoke, S. N. [1 ]
Bakhtiarizadeh, M. R. [2 ]
机构
[1] AREEO, Khuzestan Agr & Nat Resources Res & Educ Ctr, Dept Anim Sci, Ahvaz, Iran
[2] Iran Univ Tehran, Coll Aburaihan, Dept Anim Sci, Tehran, Iran
关键词
Isfahani chicken; growth; pectoralis muscle; RNA-Seq; Ross broiler; SKELETAL-MUSCLE; IDENTIFICATION; TRANSCRIPTION; PROTEIN; ACTIVATION; TISSUES; MICE; FAT;
D O I
10.1080/1828051X.2019.1634498
中图分类号
S8 [畜牧、 动物医学、狩猎、蚕、蜂];
学科分类号
0905 ;
摘要
RNA-Seq technology was used to investigate differences in the gene expression of pectoralis muscle tissue between two chicken breeds [Ross as commercial (rapidly growing) and Isfahani as Iranian local breed (slow-growing)]. Total RNA was isolated from breast muscle samples at end of 4 weeks of age and sequenced by an Illumina Hiseq 2000 sequencer. Hierarchical Indexing for Spliced Alignment of Transcripts (HISAT2) was applied to align clean reads to chicken reference genome. Then, Cufflinks package was used to assemble transcripts and identify significantly differentially expressed genes (DEGs). Between two groups, the 606 significantly DEGs were identified (p-adjusted <=.05). The confirmation of RNA-seq data was performed by Quantitative real-time PCR (qRT-PCR), consistent expression results were found for 10 selected genes. This study identified DEGs that regulate peroxisome proliferator-activated receptors (PPAR) signalling and Phosphatidylinositol-3 kinase Akt (PI3K/Akt) pathways in the Commercial breed, which might contribute to its higher metabolism of energy and growth characteristics compared to the Native breed. Our results suggested that the different expression patterns of some interesting genes including the PIK3IP1, SGK1, FOXO3, FBXO32, FBXO30, CUL3 and ASB1 in Native chicken might represent a cause for the poor growth performance for this breed than the Commercial breed.
引用
收藏
页码:1161 / 1173
页数:13
相关论文
共 50 条
  • [1] PI3K/Akt signalling pathway and cancer
    Vara, JAF
    Casado, E
    de Castro, J
    Cejas, P
    Belda-Iniesta, C
    González-Barón, M
    CANCER TREATMENT REVIEWS, 2004, 30 (02) : 193 - 204
  • [2] FHIT gene expression is repressed by mitogenic signaling through the PI3K/AKT/FOXO pathway
    Kelley, Kevin
    Berberich, Steven J.
    AMERICAN JOURNAL OF CANCER RESEARCH, 2011, 1 (01): : 62 - 70
  • [3] The relation between PI3K/AKT signalling pathway and cancer
    Noorolyai, Saeed
    Shajari, Neda
    Baghbani, Elham
    Sadreddini, Sanam
    Baradaran, Behzad
    GENE, 2019, 698 : 120 - 128
  • [4] Angelica Sinensis promotes myotube hypertrophy through the PI3K/Akt/mTOR pathway
    Yeh, Tzu-Shao
    Hsu, Cheng-Chen
    Yang, Suh-Ching
    Hsu, Mei-Chich
    Liu, Jen-Fang
    BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2014, 14
  • [5] Isorhamnetin protects against cardiac hypertrophy through blocking PI3K–AKT pathway
    Lu Gao
    Rui Yao
    Yuzhou Liu
    Zheng Wang
    Zhen Huang
    Binbin Du
    Dianhong Zhang
    Leiming Wu
    Lili Xiao
    Yanzhou Zhang
    Molecular and Cellular Biochemistry, 2017, 429 : 167 - 177
  • [6] Angelica Sinensis promotes myotube hypertrophy through the PI3K/Akt/mTOR pathway
    Tzu-Shao Yeh
    Cheng-Chen Hsu
    Suh-Ching Yang
    Mei-Chich Hsu
    Jen-Fang Liu
    BMC Complementary and Alternative Medicine, 14
  • [7] The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications
    Carnero, Amancio
    Blanco-Aparicio, Carmen
    Renner, Oliver
    Link, Wolfgang
    Leal, Juan F. M.
    CURRENT CANCER DRUG TARGETS, 2008, 8 (03) : 187 - 198
  • [8] Targeting the PI3K/Akt/mTOR signalling pathway in Cystic Fibrosis
    R. Reilly
    M. S. Mroz
    E. Dempsey
    K. Wynne
    S. J. Keely
    E. F. McKone
    C. Hiebel
    C. Behl
    J. A. Coppinger
    Scientific Reports, 7
  • [9] The Effect of Lycopene on the PI3K/Akt Signalling Pathway in Prostate Cancer
    Chen, Jiezhong
    O'Donoghue, Adam
    Deng, Yi-Fu
    Zhang, Bing
    Kent, Fanning
    O'Hare, Tim
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2014, 14 (06) : 800 - 805
  • [10] Correction to: Isorhamnetin protects against cardiac hypertrophy through blocking PI3K–AKT pathway
    Lu Gao
    Rui Yao
    Yuzhou Liu
    Zheng Wang
    Zhen Huang
    Binbin Du
    Dianhong Zhang
    Leiming Wu
    Lili Xiao
    Yanzhou Zhang
    Molecular and Cellular Biochemistry, 2022, 477 : 327 - 328